Results 41 to 50 of about 22,911 (183)

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 1

open access: yes, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958)   +11 more
core   +1 more source

The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance

open access: yesPostępy Mikrobiologii, 2021
The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj   +1 more source

Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]

open access: yes, 2022
We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad   +16 more
core   +1 more source

Meropenem-Vaborbactam as salvage therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3 [PDF]

open access: yes, 2021
A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol.
Simona Barnini   +7 more
core   +2 more sources

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

open access: yesExpert Review of Anti-infective Therapy, 2020
infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Novelli A   +3 more
openaire   +3 more sources

Mutation of kvrA causes OmpK35/36 porin downregulation and reduced meropenem/vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae [PDF]

open access: yes, 2020
Meropenem/vaborbactam resistance in Klebsiella pneumoniae is associated with loss of function mutations in the OmpK35 and OmpK36 porins. Here we identify two previously unknown loss of function mutations that confer cefuroxime resistance in K. pneumoniae.
Avison, Matthew B   +9 more
core   +1 more source

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

open access: yesInfectious Diseases and Therapy, 2018
Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink   +22 more
doaj   +1 more source

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 2

open access: yes, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958)   +11 more
core   +1 more source

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion

open access: yesAntibiotics, 2023
This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime–avibactam (CAZ-AVI) and meropenem–vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these
Andrea Marino   +12 more
doaj   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

open access: yesInfection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R   +3 more
doaj  

Home - About - Disclaimer - Privacy